Identification of Cytokine Profiles and T Cell Subsets Among Immunosuppressed Patients at Risk of Developing Active Tuberculosis
|ClinicalTrials.gov Identifier: NCT00285441|
Recruitment Status : Unknown
Verified December 2005 by Hvidovre University Hospital.
Recruitment status was: Recruiting
First Posted : February 2, 2006
Last Update Posted : February 28, 2006
|Condition or disease|
|Tuberculosis HIV Infections Rheumatoid Arthritis|
Immunosuppressed patients latently infected with TB are at higher risk of developing active TB than patients with normal immune functions. Especially two patient categories are at risk: HIV positives and patients receiving TNF-a blocking medication. Existing methods of diagnosis and surveillance of latent TB infection can not identify who will develop active TB and who can control the infection. There is a need for better understanding of TB specific immune functions,as we believe deficient TB specific immune reactions is a key in reactivation of latent TB infection.
In this study we follow groups of latent TB infected patients with either rheumatoid arthritis or HIV. We follow the patients during treatment with TNF-a blocking medication, HAART treatment or prophylactic TB medication. Results are correlated to patients with active TB, latent TB and healthy controls.
|Study Type :||Observational|
|Enrollment :||60 participants|
|Observational Model:||Defined Population|
|Study Start Date :||November 2005|
|Study Completion Date :||September 2008|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00285441
|Contact: Morten Ruhwald, MD||+45 email@example.com|
|Contact: Pernille Ravn, MD, Ph.d.||+45 firstname.lastname@example.org|
|Infectious disease department University Hospital Hvidovre||Recruiting|
|Copenhagen, Denmark, 2650|
|Principal Investigator:||Morten Ruhwald, MD||University Hospital Hvidovre|